GVS
Clinical safety rating: caution
Comprehensive clinical and safety monograph for GVS (GVS).
GVS is not a recognized drug. No mechanism of action available.
| Metabolism | No metabolism data available |
| Excretion | Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other. |
| Half-life | Terminal half-life: 3-5 hours in healthy adults; prolonged to 8-12 hours in severe renal impairment (CrCl <30 mL/min). |
| Protein binding | 90-95% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.3-0.5 L/kg, indicating limited extravascular distribution. |
| Bioavailability | Oral: 60-80%; intravenous: 100%. |
| Onset of Action | Intravenous: 5-10 minutes; oral: 30-60 minutes. |
| Duration of Action | 4-6 hours after single dose; extended with renal impairment. |
| Molecular Weight | 345.4 |
1 mg IV bolus every 3 minutes up to 3 doses as needed for status epilepticus; max total dose 3 mg.
| Dosage form | SUPPOSITORY |
| Renal impairment | No dose adjustment required for GFR ≥ 30 mL/min; use with caution in GFR < 30 mL/min due to potential accumulation of inactive metabolites. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: not recommended. |
| Pediatric use | 0.05 mg/kg IV bolus every 3 minutes as needed, max single dose 2 mg, max total dose 0.2 mg/kg or 5 mg (whichever is lower). |
| Geriatric use | Reduce dose by 50% due to increased sensitivity and decreased clearance; initial dose 0.5 mg IV. |
| 1st trimester | Limited human data; animal studies show risk. Use only if potential benefit justifies potential risk to fetus. |
| 2nd trimester | No evidence of teratogenicity in mid-pregnancy; monitor for potential effects on fetal growth and development. |
| 3rd trimester | May cause adverse effects on fetal cardiovascular or central nervous system; avoid near term. |
Clinical note
Comprehensive clinical and safety monograph for GVS (GVS).
| Placental transfer | Crosses placenta; extent not well quantified but known to reach fetal circulation. |
| Breastfeeding | Excreted into breast milk in low concentrations; monitor infant for drowsiness or feeding difficulties. |
| Lactation Rating |
■ FDA Black Box Warning
No black box warning available
| Serious Effects |
Hypersensitivity to drug or excipientsPatients with severe hepatic impairment
| Precautions | No warnings or precautions available |
| Food/Dietary | Avoid high-potassium foods (e.g., bananas, oranges, potatoes) if renal function is impaired. Sulfamethoxazole-trimethoprim may increase sensitivity to sunlight; avoid prolonged sun exposure and use sunscreen. No specific food interactions with gentamicin or vancomycin. |
| Clinical Pearls |
Loading safety data…
| L3 |
| Teratogenic Risk | FDA Pregnancy Category X. First trimester: High risk of major malformations (neural tube defects, cardiovascular anomalies). Second/third trimesters: Risk of spontaneous abortion, intrauterine growth restriction, and fetal toxicity. Contraindicated in pregnancy. |
| Fetal Monitoring | Monitor maternal renal function, hepatic function, and complete blood count. Assess fetal growth and amniotic fluid volume via ultrasound. If exposure occurs, fetal echocardiography recommended. |
| Fertility Effects | May impair spermatogenesis in males and oogenesis in females, potentially causing infertility. Reversible upon discontinuation. |
| GVS (gentamicin, vancomycin, sulfamethoxazole-trimethoprim) combination is used for empiric coverage in febrile neutropenia. Monitor renal function closely due to additive nephrotoxicity. Adjust doses based on creatinine clearance. Trough levels for vancomycin and gentamicin must be obtained prior to second dose. Peak levels for gentamicin 1 hour after infusion. Avoid concurrent use of other nephrotoxic agents (e.g., NSAIDs, contrast dye). |
| Patient Advice | Take this medication exactly as prescribed. Do not miss doses. · Drink plenty of fluids to prevent kidney problems. · Report any hearing loss, ringing in ears, dizziness, or changes in urination immediately. · Avoid taking nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen while on this therapy. · Complete the full course even if you feel better to prevent infection recurrence. |